

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION NO. FILING DATE CONFIRMATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/688,069 10/14/2000 Sai S. Subramaniam MONS:038US 8450 **EXAMINER** 11/14/2003 32425 7590 FULBRIGHT & JAWORSKI L.L.P. KALLIS, RUSSELL 600 CONGRESS AVE. **ART UNIT** PAPER NUMBER **SUITE 2400** AUSTIN, TX 78701 1638

DATE MAILED: 11/14/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/688,069	SUBRAMANIAM ET AL.
	Office Action Summary	Examiner	Art Unit
		Russell Kallis	1638
P riod f	The MAILING DATE of this communication Reply	cation appears on the cover shet wi	th the correspond nc address
THE - Ext afto - If tl - If N - Fai - Any	HORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNIC ensions of time may be available under the provisions of time may be available under the provisions of time from the mailing date of this commune period for reply specified above is less than thirty (30) to period for reply is specified above, the maximum state fure to reply within the set or extended period for reply we reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b)	CATION, of 37 CFR 1.136(a). In no event, however, may a reunication ) days, a reply within the statutory minimum of thirty lutory period will apply and will expire SIX (6) MON will, by statute, cause the application to become AB.	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication ANDONED (35 U.S.C. § 133).
1)[\]	Responsive to communication(s) file	ed on <u>08 September 2003</u> .	
2a)	This action is <b>FINAL</b> . 2	b)⊠ This action is non-final.	
3)	Since this application is in condition closed in accordance with the praction of Claims	•	
4) 🖂	Claim(s) <u>1-10,13-41 and 43-48</u> is/are	e pending in the application.	
	4a) Of the above claim(s) <u>2-9 and 13-41</u> is/are withdrawn from consideration.		
5)	5) Claim(s) is/are allowed.		
6)[	6)⊠ Claim(s) <u>1,10,43-48</u> is/are rejected.		
7)[	Claim(s) is/are objected to.		
,	Claim(s) are subject to restricti	ion and/or election requirement.	
9)[	The specification is objected to by the	Examiner.	
10)[	The drawing(s) filed on is/are: a	a)□ accepted or b)□ objected to by th	ne Examiner.
	Applicant may not request that any obje	ction to the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed	on is: a) approved b) di	sapproved by the Examiner.
	If approved, corrected drawings are requ	uired in reply to this Office action.	
12)	The oath or declaration is objected to be	by the Examiner.	
Priority	under 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim f	or foreign priority under 35 U.S.C. §	3 119(a)-(d) or (f).
a)	) All b) Some * c) None of:		
	1. Certified copies of the priority d	locuments have been received.	
	2. Certified copies of the priority d	locuments have been received in Ap	oplication No
*	•	f the priority documents have been intional Bureau (PCT Rule 17.2(a)).	
	Acknowledgment is made of a claim for	•	
	a)  The translation of the foreign lang	·	
	Acknowledgment is made of a claim fo		
Attachme	nt(s)		
2) D Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PT rmation Disclosure Statement(s) (PTO-1449) Pap	O-948) 5) Notice of Ir	Summary (PTO-413) Paper No(s)  Informal Patent Application (PTO-152)

Application/Control Number: 09/688,069

Art Unit: 1638

· •

## **DETAILED ACTION**

The finality of the last Office action has been <u>WITHDRAWN</u> in view of the new ground of rejection below. The amendment of September 2003 has been entered.

Claims 1-10, 13-41 and 43-48 are pending. Claims 2-9 and 13-41 are withdrawn and Claims 11-12 and 42 are cancelled. Claims 1, 10 and 43-48 are examined.

The rejection of Claims 10-12 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in view of Applicant's amendments.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1 and 10 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is maintained for the reasons of record set forth in the Official action mailed 6/03/2003. Applicant's arguments filed 9/08/2003 have been considered but are not deemed persuasive.

Applicant asserts that description of a tocopherol cyclase from *Synechocystis* and a putative homologue of *Arabidopsis* defines the broad category of tocopherol cyclases that spans the groups encompassing all tocopherol cyclases from all organisms or all prokaryotic organisms (response page 4). The putative *Arabidopsis* tocopherol cyclase sequence of SEQ ID NO: 109, a sequence taken from a BAC clone, does not support the description of a genus of tocopherol

Application/Control Number: 09/688,069

Art Unit: 1638

cyclase encoding polynucleotides because the specification and the prior art do not show any correlation between the *Arabidopsis* BAC sequence and the *Synechocystis* sequence, and the claimed prokaryotic unifunctional tocopherol cyclase activity and thus, Applicant has described only one tocopherol cyclase.

Claims 1 and 10 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This rejection is maintained for the reasons of record set forth in the Official action mailed 6/03/2003. Applicant's arguments filed 9/08/2003 have been considered but are not deemed persuasive.

Applicant asserts that the specification discloses how to make and use the claimed invention, including identifying tocopherol cyclase sequences, and that cells and plants have been transformed with the sequences of the present invention (response page 5). Applicant asserts that the Examiner has not indicated how the cited references of Broun, Doerks, or Smith suggest that such work would be undue experimentation (response page 6). The Examiner maintains that Applicant has not transformed plants with the *Arabidopsis* putative tocopherol cyclase gene, or evaluated the ability of this gene to either encode tocopherol cyclase or to restore tocopherol cyclase activity to knockout mutants. Applicant only transformed plants with *Arabidopsis* phytyl prenyltransferase genes, which are non-elected. The references cited by the Examiner demonstrate the unpredictability inherent in predicting gene product activity based solely on its similarity to other sequences. In the absence of a definite function, Applicant has not taught how to make and use the invention as broadly claimed.

Application/Control Number: 09/688,069

Art Unit: 1638

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless

(c) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 10 and 43-48 are rejected under 35 U.S.C. 102(e) as being anticipated by Lassner M.W. et al. U.S. Patent 6,541,259 filed April 14, 2000.

The applied reference has a common assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Lassner teaches isolation of SEQ ID NO: 38 encoding SEQ ID NO 39 from a knock out mutant of *Synechocystis* sp. 6803 (slr1737) the cells of which produced no detectable levels of tocopherol in columns 25 and 26.

All Claims are rejected.

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Kallis whose telephone number is (703) 305-5417. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0198.

Russell Kallis PhD. November 4, 2003 PRIMARY EXAMINER

GROUP 189-

GROUP 180-1638 Marie 2